$125M early stage fund seeks to invest in health startups in N.C. and southeastern U.S.

9:49 am by | 2 Comments

Hatteras Venture Partners announced Monday that the company has closed its fourth fund totaling $125 million.

The Durham, North Carolina-based venture capital firm invests in device, diagnostic, biopharma, health IT and human-health related startups primarily based in North Carolina and the southeastern U.S.

The HVP IV fund also established a HVP IV SBIC, which is the first licensee of the U.S. Small Business Administration’s (SBA) newly established Early Stage SBIC Program.


An earlier, initial closing of the HPV IV fund in 2011 led to the establishment of the Hatteras Discovery, a sub-allocation of the fourth fund, to invest in seed-stage startups. Hatteras Discovery has already invested in Clearside BiomedicalCoferon and G1 Therapeutics. The larger HPV IV fund has invested in Clinverse Inc. and co-invested with Hatteras Discovery in Clearside and Coferon.

“We are gratified to achieve our fund target of $125 million,” said Bob Ingram, general partner in a news release. “These funds will allow us to drive the numerous seed and early stage opportunities we are identifying in the human medicine life science field.  During our fundraising process, our deal flow has grown substantially in number and quality.”

Founded in 2000, Hatteras has more than $250 million under management.

Copyright 2015 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Arundhati Parmar

By Arundhati Parmar

Arundhati Parmar is the Medical Devices Reporter at MedCity News. She has covered medical technology since 2008 and specialized in business journalism since 2001. Parmar has three degrees from three continents - a Bachelor of Arts in English from Jadavpur University, Kolkata, India; a Masters in English Literature from the University of Sydney, Australia and a Masters in Journalism from Northwestern University in Chicago. She has sworn never to enter a classroom again.
More posts by Author


Arundhati, great article! But TYPO in beginning of third paragraph--you have "HPV"--should be HVP. Don't think the fund wants the acronym for human papilloma virus!